ALPHA TAU SUBMITS FIRST PRE-MARKET APPROVAL MODULE TO THE FDA FOR ALPHA DART® FOR THE TREATMENT OF RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

Reuters · 4d ago

Please log in to view news